Skip to main content
SpringerLink
Log in

Practice and principle of traditional Chinese medicine for the prevention and treatment of COVID-19

  • Review
  • Published:
Frontiers of Medicine Aims and scope Submit manuscript

Abstract

Traditional Chinese medicine (TCM) has played an important role in the prevention and treatment of Coronavirus disease 2019 (COVID-19) epidemic in China. The integration of Chinese and Western medicine is an important feature of Chinese COVID-19 prevention and treatment. According to a series of evidence-based studies, TCM can reduce the infection rate of severe acute respiratory syndrome coronavirus 2 in high-risk groups. For patients with mild and moderate forms of COVID-19, TCM can relieve the related signs and symptoms, shorten the period of nucleic-acid negative conversion, and reduce conversion rate to the severe form of the disease. For COVID-19 patients with severe and critical illnesses, TCM can improve inflammatory indicators and blood oxygen saturation, shorten the hospital stay, and reduce the mortality rate. During recovery, TCM can improve patients’ symptoms, promote organ function recovery, boost the quality of patients’ life, and reduce the nucleic-acid repositive conversion rate. A series of mechanism research studies revealed that capability of TCM to treat COVID-19 through antiviral and anti-inflammatory effects, immune regulation, and protection of organ function via a multicomponent, multitarget, and multipathway approach.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8(4): 420–422

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Zheng Y, Jin D, Lin J, Zhang Y, Tian J, Lian F, Tong X. Understanding COVID-19 in Wuhan from the perspective of cold-dampness: clinical evidences and mechanisms. Front Med (Lausanne) 2021; 8: 617659

    Article  PubMed  Google Scholar 

  3. Qiao Y, Xu X, Zhou F, Wang K, Li M, Liu C, Chen Z, Yin P, Shi Y, Wang Y, Liu Q. Effect of Lianhua Qingwen capsules on the positive rate of COVID-19 close contacts: a retrospective analysis of a large-scale population-based cohort study. Phytomedicine 2023; 112: 154690

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Huang B, Li N. Wuchang model: traditional Chinese medicine guards the community gate. Chin News Tradit Chin Med (Zhongguo Zhong Yi Yao Bao) 2020; 2020–04–01(01) (in Chinese)

  5. Shah MR, Fatima S, Khan SN, Ullah S, Himani G, Wan K, Lin T, Lau JYN, Liu Q, Lam DSC. Jinhua Qinggan granules for non–hospitalized COVID-19 patients: a double–blind, placebo-controlled, and randomized controlled trial. Front Med (Lausanne) 2022; 9: 928468

    Article  PubMed  Google Scholar 

  6. Liu Z, Li X, Gou C, Li L, Luo X, Zhang C, Zhang Y, Zhang J, Jin A, Li H, Zeng Y, Li T, Wang X. Effect of Jinhua Qinggan granules on novel coronavirus pneumonia in patients. J Tradit Chin Med 2020; 40(3): 467–472

    PubMed  Google Scholar 

  7. Lin TPH, Lau EMC, Wan KH, Zhong L, Leung E, Ko CN, Lu A, Shah MR, Bian Z, Lam DSC. Initial observations of Jinhua Qinggan Granules, a Chinese medicine, in the mitigation of hospitalization and mortality in high–risk elderly with COVID-19 infection: a retrospective study in an old age home in Hong Kong. Front Med (Lausanne) 2022; 9: 948149

    Article  PubMed  Google Scholar 

  8. Li H, Lv WL, Sun YN, Xiao Y, Yang W, Yang HJ, Gao QH, Yang ZQ, Lv WL, Ling RJ, Shou ZX, Hu JC, Zhao XF, Ma YG, Liu MY, Luo ZW, Cheng BJ, Liu L, Shen F, Zhang SY, Zeng JQ, Xiang Y, Huang CQ, Yang Q, Ding X, Qing LX, Wang RL. Real-world clinical study of traditional Chinese medicine treatment for 749 patients with coronavirus disease 2019. Chin J Tradit Chin Med Pharm (Zhonghua Zhong Yi Yao Za Zhi) 2020; 35(6): 3194–3198 (in Chinese)

    Google Scholar 

  9. Tian J, Yan S, Wang H, Zhang Y, Zheng Y, Wu H, Li X, Gao Z, Ai Y, Gou X, Zhang L, He L, Lian F, Liu B, Tong X. Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: a cohort study. Pharmacol Res 2020; 161: 105127

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Zhang Y, Liu Y, Li M, Feng S, Li X, Gao Z, Yang Y, Tong X. Timely treatment and higher compliance to traditional Chinese medicine: new influencing factors for reducing severe COVID-19 based on retrospective cohorts in 2020 and 2021. Pharmacol Res 2022; 178: 106174

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Peng W, Yang F, Zheng W, Feng J, Xu Q, Zhang L. Clinical efficacy evaluation of Xuanfei-Baidu granules in the treatment of novel coronavirus pneumonia infected with Omicron strain. Tianjin J Tradit Chin Med (Tianjin Zhong Yi Yao) 2021; 39(9): 1093–1098 (in Chinese)

    Google Scholar 

  12. Xiong X, Wang P, Su K, Cho WC, Xing Y. Chinese herbal medicine for coronavirus disease 2019: a systematic review and meta–analysis. Pharmacol Res 2020; 160: 105056

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Chen G, Su W, Yang J, Luo D, Xia P, Jia W, Li X, Wang C, Lang S, Meng Q, Zhang Y, Ke Y, Fan A, Yang S, Zheng Y, Fan X, Qiao J, Lian F, Wei L, Tong X. Chinese herbal medicine reduces mortality in patients with severe and critical coronavirus disease 2019: a retrospective cohort study. Front Med 2020; 14(6): 752–759

    Article  PubMed  PubMed Central  Google Scholar 

  14. Sun QG, An XD, Xie P, Jiang B, Tian JX, Yang Q, Li XY, Luo M, Liu P, Zhao SH, Duan LY, Lang SP, Fan A, Luo PC, Lian FM, Huang XD, Tong XL. Traditional Chinese medicine decoctions significantly reduce the mortality in severe and critically ill patients with COVID-19: a retrospective cohort study. Am J Chin Med 2021; 49(5): 1063–1092

    Article  CAS  PubMed  Google Scholar 

  15. Liu Y. Clinical effect analysis of Western Medicine combined with Huashi–Du–du prescription in the treatment of severe novel coronavirus pneumonia. Lab Med Clin (Jian Yan Yi Xue Yu Lin Chuang) 2021; 18(8): 1152–1153 (in Chinese)

    MathSciNet  CAS  Google Scholar 

  16. Shi N, Guo L, Liu B, Bian Y, Chen R, Chen S, Chen Y, Chen Y, Cong X, Dong G, Guo J, Hu L, Jiang J, Leng L, Li B, Li D, Li H, Li J, Li L, Liu J, Lu C, Lv W, Miao Q, Qi W, Shi Z, Shi J, Shi H, Tian Y, Wang B, Wang G, Wang J, Wang W, Xian Y, Xie X, Xiong Y, Xu C, Xu M, Yan B, Yang J, Zhang L, Zhou Z, Zhu H, Huang L. Efficacy and safety of Chinese herbal medicine versus Lopinavir-Ritonavir in adult patients with coronavirus disease 2019: a non-randomized controlled trial. Phytomedicine 2021; 81: 153367

    Article  CAS  PubMed  Google Scholar 

  17. Wang J, Lin L, Li B, Wang J, Yang C, Zhang G. Research and development progress of traditional Chinese medicine for prevention and treatment of coronavirus disease 2019 (COVID-19). J Shenyang Pharm Univ (Shenyang Yao Ke Da Xue Xue Bao) 2021; 38(7): 751–761 (in Chinese)

    Google Scholar 

  18. Shang T, Yu Q, Ren T, Wang XT, Zhu H, Gao JM, Pan G, Gao X, Zhu Y, Feng Y, Li MC. Xuebijing Injection maintains GRP78 expression to prevent Candida albicans-induced epithelial death in the kidney. Front Pharmacol 2020; 10: 1416

    Article  PubMed  PubMed Central  Google Scholar 

  19. Ma Q, Qiu M, Zhou H, Chen J, Yang X, Deng Z, Chen L, Zhou J, Liao Y, Chen Q, Zheng Q, Cai L, Shen L, Yang Z. The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical corona virus disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2. Pharmacol Res 2020; 160: 105073

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Zhou S, Feng J, Xie Q, Huang T, Xu X, Zhou D, Zhang W, Sun S, Liu X, Wu X, Che J, Fan T, Zou D, Wang J, Zhan D, Peng D, Feng Y, Yu G, Yuan Z, Fang B. Traditional Chinese medicine shenhuang granule in patients with severe/critical COVID-19: a randomized controlled multicenter trial. Phytomedicine 2021; 89: 153612

    Article  PubMed  PubMed Central  Google Scholar 

  21. Yang Y, Ding L, Bao T, Li Y, Ma J, Li Q, Gao Z, Song S, Wang J, Zhao J, Wang Z, Zhao D, Li X, Wang Z, Zhao L, Tong X. Network pharmacology and experimental assessment to explore the pharmacological mechanism of Qimai Feiluoping Decoction against pulmonary fibrosis. Front Pharmacol 2021; 12: 770197

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. An X, Duan L, Zhang YH, Jin D, Zhao S, Zhou RR, Duan Y, Lian F, Tong X. The three syndromes and six Chinese patent medicine study during the recovery phase of COVID-19. Chin Med 2021; 16(1): 44

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. An X, Peng B, Huang X, Jiang H, Xiong Z, Zhang H, Lian F, Ba Y, Tong X. Ludangshen oral liquid for treatment of convalescent COVID-19 patients: a randomized, double–blind, placebo-controlled multicenter trial. Chin Med 2022; 17(1): 42

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Li K, Walczak-Kozłowska T, Lipowski M, Li J, Krokosz D, Su Y, Yu H, Fan H. The effect of the Baduanjin exercise on COVID-19-related anxiety, psychological well-being and lower back pain of college students during the pandemic. BMC Sports Sci Med Rehabil 2022; 14(1): 102

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Tang Y, Jiang J, Shen P, Li M, You H, Liu C, Chen L, Wang Z, Zhou C, Feng Z. Liuzijue is a promising exercise option for rehabilitating discharged COVID-19 patients. Medicine (Baltimore) 2021; 100(6): e24564

    Article  CAS  PubMed  Google Scholar 

  26. Yang C, Ma Y, Mei J, Gong X, Wang M, Liu K. Effect of Baduanjin combined with auricular point sticking therapy on coronavirus disease 2019 with insomnia. Chin Acupunct Moxibustion (Zhongguo Zhen Jiu) 2021; 41(3): 243–246 (in Chinese)

    Google Scholar 

  27. Shu C, Feng S, Cui Q, Cheng S, Wang Y. Impact of Tai Chi on CRP, TNF-α and IL-6 in inflammation: a systematic review and meta-analysis. Ann Palliat Med 2021; 10(7): 7468–7478

    Article  PubMed  Google Scholar 

  28. Liang IJ, Perkin OJ, McGuigan PM, Thompson D, Western MJ. Feasibility and acceptability of home-based exercise snacking and Tai Chi snacking delivered remotely to self-isolating older adults during COVID-19. J Aging Phys Act 2022; 30(1): 33–43

    Article  PubMed  Google Scholar 

  29. Zhang JW, Lv SJ, Ma J, Wei QY, Cui MZ, Li YM, Chen ZH, Yuan W. Study on the relationship between different exercise interventions and quality of life in patients with coronary heart disease at home during the epidemic of COVID-19. Chin J Rehabil Med (Zhongguo Kang Fu Yi Xue Za Zhi) 2021; 37(2): 176–182 (in Chinese)

    Google Scholar 

  30. He S, Tian J, Li X, Zhou Y, Xiao M, Zhang Y, Min X, Li X, Jin D, Zhang Q, Zheng Y, Ke J, Li Q, Tao J, Song P, Wang H, Lv Y, Ding Q, Tang S, Lin J, Jiang Z, Zhang Z, Song J, Lian F, Tong X. Positive RT-PCR test results in 420 patients recovered from COVID-19 in Wuhan: an observational study. Front Pharmacol 2020; 11: 549117

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Li X, Liu B, Wang Y, Guan L, Li G, Wang H, Wang J, Ong C, Xiao M, Tong X. Interpretation of the Guidance and Suggestions of Traditional Chinese Medicine Rehabilitation during the Convalescence of Novel Coronavirus Pneumonia (Trial). J Tradit Chin Med (Zhong Yi Za Zhi) 2020; 61(11): 928–934 (in Chinese)

    Google Scholar 

  32. Shi X, Tong X, Sun G, Liu B, Wang H, Yu X, Wu H, Gao S, Wang L, Fang J, Yu S, Liang F, Ji L, Jing X, Zhou Z, Ma J, Chang X, Zhang W, Yang J, Chen R, Zhao J, Zhao H, Zhao B, Wang F, Liang F, Li X, Yang Y, Liu W, Wen B. Guidance on acupuncture and moxibustion intervention for coronavirus disease 2019 (second edition). Chin Acupunct Moxibustion (Zhongguo Zhen Jiu) 2020; 40(5): 462–463 (in Chinese)

    Google Scholar 

  33. Yan L, Li Z, Zhang Y, Liang X, Li J, Wu M, Shi G, Chen R, Ji Xg, Zuo S, Chen S, Zhou P, Fu W. Shukan Tiaoshen acupuncture combined with western medicine in the treatment of depression and insomnia comorbidity caused by COVID-19 isolation experience: a multicenter randomized controlled trial. Chin Acupunct Moxibustion (Zhongguo Zhen Jiu) 2023; 43(3): 255–260 (in Chinese)

    Google Scholar 

  34. Feng B, Zheng D, Yang L, Su Z, Tang L, Zhu Y, Xu X, Wang Q, Lin Q, Hu J, Lin M, Huang L, Zhou X, Liu H, Li S, Pan W, Shi R, Lu Y, Wu B, Ding B, Wang Z, Guo J, Zhang Z, Zheng G, Liu Y. Post-hospitalization rehabilitation alleviates long-term immune repertoire alteration in COVID-19 convalescent patients. Cell Prolif 2023; 56(10): e13450

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Xu X, Wu H, Jin G, Huang J, Li J, Zhou J, Cao M, Sun D, Zhang W, Peng W, Pu Y, Chen C, Sun Y, Yang H, Zhou S, Fang B. Efficacy of Lianhua Qingwen for children with SARS-CoV-2 Omicron infection: a propensity score-matched retrospective cohort study. Phytomedicine 2023; 111: 154665

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Chen J, Tang Q, Zhang B, Yuan S, Chen J, Shen S, Wang D, Lin J, Dong H, Yin Y, Gao J. Huashi baidu granule in the treatment of pediatric patients with mild coronavirus disease 2019: a single-center, open-label, parallel-group randomized controlled clinical trial. Front Pharmacol 2023; 14: 1092748

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. An X, Xu X, Xiao M, Min X, Lyu Y, Tian J, Ke J, Lang S, Zhang Q, Fan A, Liu B, Zhang Y, Hu Y, Zhou Y, Shao J, Li X, Lian F, Tong X. Efficacy of Jinhua Qinggan Granules combined with western medicine in the treatment of confirmed and suspected COVID-19: a randomized controlled trial. Front Med (Lausanne) 2021; 8: 728055

    Article  PubMed  Google Scholar 

  38. Duan C, Xia W, Zheng C, Sun G, Li Z, Li Q, Li P, Zhang H, Yang F, Zhang B, Liu Q. Clinical observation of Jinhua Qinggan granule combined with conventional western medicine in the treatment of mild coronavirus disease 2019. J Tradit Chin Med (Zhong Yi Za Zhi) 2020; 61(17): 1473–1477 (in Chinese)

    Google Scholar 

  39. Xia W, Zheng C, Zhang J, Huang M, Li Q, Duan C, Li Z, Fan C, Zou Y, Xu B, Yang F, Liu Q. Randomized controlled study of a diagnosis and treatment plan for moderate coronavirus disease 2019 that integrates traditional Chinese and western medicine. J Tradit Chin Med 2022; 42(2): 234–241

    PubMed Central  Google Scholar 

  40. Xiao M, Tian J, Zhou Y, Xu X, Min X, Lv Y, Peng M, Zhang Y, Yan D, Lang S, Zhang Q, Fan A, Ke J, Li X, Liu B, Jiang M, Liu Q, Zhu J, Yang L, Zhu Z, Zeng K, Li C, Zheng Y, Wu H, Lin J, Lian F, Li X, Tong X. Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: a randomized controlled trial. Pharmacol Res 2020; 161: 105126

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Zhang XY, Lv L, Zhou YL, Xie LD, Xu Q, Zou XF, Ding Y, Tian J, Fan JL, Fan HW, Yang YX, Ye XQ. Efficacy and safety of Xiyanping injection in the treatment of COVID-19: a multicenter, prospective, open-label and randomized controlled trial. Phytother Res 2021; 35(8): 4401–4410

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Fu XX, Lin LP, Tan XH. Clinical study on 37 cases of COVID-19 treated with integrated traditional Chinese and western medicine. Tradit Chin Drug Res Clinic Pharmacol (Zhong Yao Xin Yao Yu Lin Chuang Yao Li) 2020; 31: 600–604 (in Chinese)

    CAS  Google Scholar 

  43. Qiu M, Li QT, Zhu DP, Wang CH, Sun QZ, Qian CF, Zhang LL, Ran J, Wang P, Tao Y, Li YP. Efficacy observation of Maxing Xuanfei Jiedu Decoction on moderate COVID-19. J Emergency Tradit Chin Med (Zhongguo Zhong Yi Ji Zheng) 2020; 29: 1129–1130, 1132 (in Chinese)

    Google Scholar 

  44. Sun HM, Xu F, Zhang L, Wei C, Chen JY, Wang QX, Jia ZH. Study on clinical efficacy of Lianhua Qingke Granule in treatment of mild and ordinary COVID-19. Chin J Exp Tradit Med Form (Zhongguo Shi Yan Fang Ji Xue Za Zhi) 2020; 26: 29–34 (in Chinese)

    Google Scholar 

  45. Yu P, Li YZ, Wang SB, Wang Y. Effect of Lianhua Qingwen Granules plus Abidol on treatment of mild coronavirus disease 2019. Chin Med J (Zhonghua Yi Xue Za Zhi) 2020; 55: 1042–1045 (in Chinese)

    Google Scholar 

  46. Li M, Zhu H, Liu Y, Lu Y, Sun M, Zhang Y, Shi J, Shi N, Li L, Yang K, Sun X, Liu J, Ge L, Huang L. Role of traditional Chinese medicine in treating severe or critical COVID-19: a systematic review of randomized controlled trials and observational studies. Front Pharmacol 2022; 13: 926189

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Kang X, Jin D, Jiang L, Zhang Y, Zhang Y, An X, Duan L, Yang C, Zhou R, Duan Y, Sun Y, Lian F. Efficacy and mechanisms of traditional Chinese medicine for COVID-19: a systematic review. Chin Med 2022; 17(1): 30

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Luo X, Ni X, Lin J, Zhang Y, Wu L, Huang D, Liu Y, Guo J, Wen W, Cai Y, Chen Y, Lin L. The add-on effect of Chinese herbal medicine on COVID-19: a systematic review and meta-analysis. Phytomedicine 2021; 85: 153282

    Article  CAS  PubMed  Google Scholar 

  49. Liu M, Gao Y, Yuan Y, Yang K, Shi S, Zhang J, Tian J. Efficacy and safety of integrated traditional Chinese and western medicine for corona virus disease 2019 (COVID-19): a systematic review and meta-analysis. Pharmacol Res 2020; 158: 104896

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Wang F, Guo Y, Jiao LW, Zhang XY, Liang N, Li G, Zong XY, Luan XJ, Zhang L, Wang JY, Chen RB, Li HZ, Fan YP, Zhao C, Xiao FR, Huang J, Xiao YH, Wang YZ, Zhang LS, Hu YH, Sun S, Wang MX, Bai WG, Ma Y, Shi NN, Ge YW, Zhang HM, Llin G, Wang YP, Wang YY. Retrospective analysis of clinical efficacy of Qingfei Paidu decoction combined with conventional western medicine in the treatment of 50 cases of severe coronavirus disease 2019. J Tradit Chin Med (Zhong Yi Za Zhi) 2021; 62(20): 1801–1805 (in Chinese)

    Google Scholar 

  51. Huang W, Jiang B, Luo J, Luo M, Ding X, Yang Q, Zhao LH, Sun QG, Tong XL. Treatment of COVID-19 in hemodialysis patients using traditional Chinese medicine: a single-center, retrospective study. Front Pharmacol 2022; 13: 764305

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Li Q, Wang H, Li X, Zheng Y, Wei Y, Zhang P, Ding Q, Lin J, Tang S, Zhao Y, Zhao L, Tong X. The role played by traditional Chinese medicine in preventing and treating COVID-19 in China. Front Med 2020; 14(5): 681–688

    Article  PubMed  PubMed Central  Google Scholar 

  53. Wang R, Stephen P, Tao Y, Zhang W, Lin SX. Human endeavor for anti-SARS-CoV-2 pharmacotherapy: a major strategy to fight the pandemic. Biomed Pharmacother 2021; 137: 111232

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qinhai M, Yongxia S, Chufang L, Jin Z, Zhenhua J, Haiming J, Kui Z, Shuxiang H, Jun D, Xiaobo L, Xiaotao H, Lin W, Nanshan Z, Zifeng Y. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res 2020; 156: 104761

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Fu L, Shao S, Feng Y, Ye F, Sun X, Wang Q, Yu F, Wang Q, Huang B, Niu P, Li X, Wong CCL, Qi J, Tan W, Gao GF. Mechanism of microbial metabolite leupeptin in the treatment of COVID-19 by traditional Chinese medicine herbs. MBio 2021; 12(5): e0222021

    Article  PubMed  Google Scholar 

  56. Ma Q, Qiu M, Zhou H, Chen J, Yang X, Deng Z, Chen L, Zhou J, Liao Y, Chen Q, Zheng Q, Cai L, Shen L, Yang Z. The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical corona virus disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2. Pharmacol Res 2020; 160: 105073

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Yeh YC, Doan LH, Huang ZY, Chu LW, Shi TH, Lee YR, Wu CT, Lin CH, Chiang ST, Liu HK, Chuang TH, Ping YH, Liu HS, Huang CF. Honeysuckle (Lonicera japonica) and Huangqi (Astragalus membranaceus) suppress SARS-CoV-2 entry and COVID-19 related cytokine storm in vitro. Front Pharmacol 2022; 12: 765553

    Article  PubMed  PubMed Central  Google Scholar 

  58. Tang WF, Tsai HP, Chang YH, Chang TY, Hsieh CF, Lin CY, Lin GH, Chen YL, Jheng JR, Liu PC, Yang CM, Chin YF, Chen CC, Kau JH, Hung YJ, Hsieh PS, Horng JT. Perilla (Perilla frutescens) leaf extract inhibits SARS-CoV-2 via direct virus inactivation. Biomed J 2021; 44(3): 293–303

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Xu H, Li S, Liu J, Cheng J, Kang L, Li W, Zhong Y, Wei C, Fu L, Qi J, Zhang Y, You M, Zhou Z, Zhang C, Su H, Yao S, Zhou Z, Shi Y, Deng R, Lv Q, Li F, Qi F, Chen J, Zhang S, Ma X, Xu Z, Li S, Xu Y, Peng K, Shi Y, Jiang H, Gao GF, Huang L. Bioactive compounds from Huashi Baidu decoction possess both antiviral and anti-inflammatory effects against COVID-19. Proc Natl Acad Sci USA 2023; 120(18): e2301775120

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Lv Y, Wang S, Liang P, Wang Y, Zhang X, Jia Q, Fu J, Han S, He L. Screening and evaluation of anti-SARS-CoV-2 components from Ephedra sinica by ACE2/CMC-HPLC-IT-TOF-MS approach. Anal Bioanal Chem 2021; 413(11): 2995–3004

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. He MF, Liang JH, Shen YN, Zhang JW, Liu Y, Yang KY, Liu LC, Wang J, Xie Q, Hu C, Song X, Wang Y. Glycyrrhizin inhibits SARS-CoV-2 entry into cells by targeting ACE2. Life (Basel) 2022; 12(11): 1706

    CAS  PubMed  ADS  Google Scholar 

  62. Yu S, Zhu Y, Xu J, Yao G, Zhang P, Wang M, Zhao Y, Lin G, Chen H, Chen L, Zhang J. Glycyrrhizic acid exerts inhibitory activity against the spike protein of SARS-CoV-2. Phytomedicine 2021; 85: 153364

    Article  CAS  PubMed  Google Scholar 

  63. Yang C, Pan X, Xu X, Cheng C, Huang Y, Li L, Jiang S, Xu W, Xiao G, Liu S. Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein. Signal Transduct Target Ther 2020; 5(1): 220

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Xu T, Meng JR, Cheng W, Liu J, Chu J, Zhang Q, Ma N, Bai L, Guo Y. Discovery of honokiol thioethers containing 1,3,4-oxadiazole moieties as potential α-glucosidase and SARS-CoV-2 entry inhibitors. Bioorg Med Chem 2022; 67: 116838

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Dai W, Zhang B, Jiang XM, Su H, Li J, Zhao Y, Xie X, Jin Z, Peng J, Liu F, Li C, Li Y, Bai F, Wang H, Cheng X, Cen X, Hu S, Yang X, Wang J, Liu X, Xiao G, Jiang H, Rao Z, Zhang LK, Xu Y, Yang H, Liu H. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 2020; 368(6497): 1331–1335

    Article  CAS  PubMed  ADS  Google Scholar 

  66. Li C, Li Y, Zhang H, Zhuo Y, Zhang L, Yang L, Gao Q, Tu Z, Shao R, Wang Y, Zhang J, Cui L, Zhang S. Xuanfei Baidu Decoction suppresses complement overactivation and ameliorates IgG immune complex-induced acute lung injury by inhibiting JAK2/STAT3/SOCS3 and NF-κB signaling pathway. Phytomedicine 2023; 109: 154551

    Article  CAS  PubMed  Google Scholar 

  67. Zhu Y, Luo L, Zhang M, Song X, Wang P, Zhang H, Zhang J, Liu D. Xuanfei Baidu Formula attenuates LPS-induced acute lung injury by inhibiting the NF-κB signaling pathway. J Ethnopharmacol 2023; 301: 115833

    Article  CAS  PubMed  Google Scholar 

  68. Zhou M, Liu Y, Qin H, Shang T, Xue Z, Yang S, Zhang H, Yang J. Xuanfei Baidu Decoction regulates NETs formation via CXCL2/CXCR2 signaling pathway that is involved in acute lung injury. Biomed Pharmacother 2023; 161: 114530

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Xiong L, Cao J, Yang X, Chen S, Wu M, Wang C, Xu H, Chen Y, Zhang R, Hu X, Chen T, Tang J, Deng Q, Li D, Yang Z, Xiao G, Zhang X. Exploring the mechanism of action of Xuanfei Baidu granule (XFBD) in the treatment of COVID-19 based on molecular docking and molecular dynamics. Front Cell Infect Microbiol 2022; 12: 965273

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Zhu Y, Han Q, Wang L, Wang B, Chen J, Cai B, Wu C, Zhu X, Liu F, Han D, Dong H, Jia Y, Liu Y. Jinhua Qinggan granules attenuates acute lung injury by promotion of neutrophil apoptosis and inhibition of TLR4/MyD88/NF-κB pathway. J Ethnopharmacol 2023; 301: 115763

    Article  CAS  PubMed  Google Scholar 

  71. Zhou W, Lai X, Wang X, Yao X, Wang W, Li S. Network pharmacology to explore the anti-inflammatory mechanism of Xuebijing in the treatment of sepsis. Phytomedicine 2021; 85: 153543

    Article  CAS  PubMed  Google Scholar 

  72. Chen X, Feng Y, Shen X, Pan G, Fan G, Gao X, Han J, Zhu Y. Anti-sepsis protection of Xuebijing injection is mediated by differential regulation of pro- and anti-inflammatory Th17 and T regulatory cells in a murine model of polymicrobial sepsis. J Ethnopharmacol 2018; 211: 358–365

    Article  PubMed  Google Scholar 

  73. Shi X, Chen G, Wei J, Feng D, Chen Y, Zhou H, Liu M, Lv X. UHPLC-Q-TOF MS-based metabolic analysis for the therapeutic efficacy of “Xuebijing Injection” against sepsis-induced acute lung injury. Evid Based Complement Alternat Med 2018; 2018: 8514619

    Article  PubMed  PubMed Central  Google Scholar 

  74. Zhang F, Guo F, Zhang Y, Xu H, Liu Y, Lin L, Li H, Yang H, Huang L. Huashibaidu formula attenuates sepsis-induced acute lung injury via suppressing cytokine storm: implications for treatment of COVID-19. Phytomedicine 2023; 109: 154549

    Article  CAS  PubMed  Google Scholar 

  75. Wu Y, Xu L, Cao G, Min L, Dong T. Effect and mechanism of Qingfei Paidu Decoction in the management of pulmonary fibrosis and COVID-19. Am J Chin Med 2022; 50(1): 33–51

    Article  PubMed  Google Scholar 

  76. Tian S, Zheng N, Zu X, Wu G, Zhong J, Zhang J, Sheng L, Liu W, Wang C, Ge G, Han J, Zhao J, Li H, Zhang W. Integrated hepatic single-cell RNA sequencing and untargeted metabolomics reveals the immune and metabolic modulation of Qing-Fei-Pai-Du decoction in mice with coronavirus-induced pneumonia. Phytomedicine 2022; 97: 153922

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Wu G, Zhang W, Zheng N, Zu X, Tian S, Zhong J, Zhang Y, Liao J, Sheng L, Ge G, Li H, Zhang W. Integrated microbiome and metabolome analysis reveals the potential therapeutic mechanism of Qing-Fei-Pai-Du decoction in mice with coronavirus-induced pneumonia. Front Cell Infect Microbiol 2022; 12: 950983

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Ma L, Zhao X, Liu T, Wang Y, Wang J, Kong L, Zhao Q, Chen Y, Chen L, Zhang H. Xuanfei Baidu decoction attenuates intestinal disorders by modulating NF-κB pathway, regulating T cell immunity and improving intestinal flora. Phytomedicine 2022; 101: 154100

    Article  CAS  PubMed  Google Scholar 

  79. He Q, Shi Y, Xing H, Tang Q, Liu J, Li C, Zhang H, Zhang B, Zhang J, Chen X. Modulating effect of Xuanfei Baidu granule on host metabolism and gut microbiome in rats. Front Pharmacol 2022; 13: 922642

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Wang Y, Wang X, Li Y, Xue Z, Shao R, Li L, Zhu Y, Zhang H, Yang J. Xuanfei Baidu Decoction reduces acute lung injury by regulating infiltration of neutrophils and macrophages via PD-1/IL17A pathway. Pharmacol Res 2022; 176: 106083

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Yan H, Lu J, Wang J, Chen L, Wang Y, Li L, Miao L, Zhang H. Prevention of cyclophosphamide-induced immunosuppression in mice with traditional Chinese medicine Xuanfei Baidu Decoction. Front Pharmacol 2021; 12: 730567

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Song L, Han B. Effects of Xuebijing injection on lipopolysaccharide (LPS)-induced nitric oxide (NO) production and expression of iNOS and nuclear factor-κB in vascular endothelial cells. J Jilin Univ (Medical Edition) (Jilin Da Xue Xue Bao Yi Xue Ban) 2014; 40(5): 997–1001 (in Chinese)

    Google Scholar 

  83. Wang Y, Sang X, Shao R, Qin H, Chen X, Xue Z, Li L, Wang Y, Zhu Y, Chang Y, Gao X, Zhang B, Zhang H, Yang J. Xuanfei Baidu Decoction protects against macrophages induced inflammation and pulmonary fibrosis via inhibiting IL-6/STAT3 signaling pathway. J Ethnopharmacol 2022; 283: 114701

    Article  CAS  PubMed  Google Scholar 

  84. Wu Y, Xu L, Cao G, Min L, Dong T. Effect and mechanism of Qingfei Paidu Decoction in the management of pulmonary fibrosis and COVID-19. Am J Chin Med 2022; 50(1): 33–51

    Article  PubMed  Google Scholar 

  85. Tong XL, Zhu X, Zhao L, Li QW, Lei Y, Song B, Shao JZ, Wang Q, Li XY, Zheng YJ, Fan AH. Strategic thinking on strengthening the construction of TCM emergency prevention and control system for emerging infectious diseases in China. Bulletin Chin Aca Sci (Zhongguo Ke Xue Yuan Yuan Kan) 2020; 35(9): 1087–1095 (in Chinese)

    Google Scholar 

  86. Li XD, Liu BY, Wang H, Shao JZ, Song B, He LY, Lian FM, Li YY. Discussion on the significance of “Wuchang model” in the prevention and control of sudden acute infectious diseases from the perspective of preventive treatment. J Nanjing Univ Chin Med (Nanjing Zhong Yi Yao Da Xue Xue Bao) 2021; 37(1): 1–5 (in Chinese)

    Google Scholar 

  87. Su HX, Yao S, Zhao WF, Li MJ, Liu J, Shang WJ, Xie H, Ke CQ, Hu HC, Gao MN, Yu KQ, Liu H, Shen JS, Tang W, Zhang LK, Xiao GF, Ni L, Wang DW, Zuo JP, Jiang HL, Bai F, Wu Y, Ye Y, Xu YC. Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol Sin 2020; 41(9): 1167–1177

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Yuan C, Zhang W, Wang J, Huang C, Shu B, Liang Q, Huang T, Wang J, Shi Q, Tang D, Wang Y. Chinese medicine phenomics (chinmedphenomics): personalized, precise and promising. Phenomics 2022; 2(6): 383–388

    Article  PubMed  PubMed Central  Google Scholar 

  89. Xu H, Zhang Y, Wang P, Zhang J, Chen H, Zhang L, Du X, Zhao C, Wu D, Liu F, Yang H, Liu C. A comprehensive review of integrative pharmacology-based investigation: a paradigm shift in traditional Chinese medicine. Acta Pharm Sin B 2021; 11(6): 1379–1399

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by National Key Research and Development Han—ateatcgic International Science and Technology Innovation Cooperation Key Project “Ineernational Cooperation Research on the Mechanism of the Treatment of COVID-19 by Hanshiyi Formula” (No. 2021YFE0201100), National Key Research and Development Plan — “Public Safety Risk Control and Emergency Technical Equipment” Key Project Special “Demonstration Research on New Drug Development of Sanhan Huashi Granules for the treatment of COVID-19” (No. 2022YFC0868300).

Author information

Author notes

  1. Linhua Zhao, Chuanxi Tian, and Yingying Yang contributed equally to this work.

Authors and Affiliations

  1. Institute of Metabolic Diseases, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China

    Linhua Zhao, Chuanxi Tian, Yu Wei, Yuxin Zhang, Xiaomin Kang, Ling Zhou, Qingwei Li, Li Wan & Xiaolin Tong

  2. Beijing University of Chinese Medicine, Beijing, 100029, China

    Chuanxi Tian, Yu Wei, Xiaomin Kang & Li Wan

  3. National Center for Integrative Medicine, China-Japan Friendship Hospital, Beijing, 100029, China

    Yingying Yang

  4. College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, 130117, China

    Huifang Guan & Jing Ma

  5. College of Traditional Chinese Medicine, Anhui University of Chinese Medicine, Hefei, 230012, China

    Yujiao Zheng

Authors
  1. Linhua Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chuanxi Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yingying Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Huifang Guan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuxin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiaomin Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ling Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Qingwei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jing Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Li Wan
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yujiao Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Xiaolin Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiaolin Tong.

Ethics declarations

Conflicts of Interests Linhua Zhao, Chuanxi Tian, Yingying Yang, Huifang Guan, Yu Wei, Yuxin Zhang, Xiaomin Kang, Ling Zhou, Qingwei Li, Jing Ma, Li Wan, Yujiao Zheng, and Xiaolin Tong declare that they have no competing interests.

This manuscript is a review article and does not involve a research protocol that requires the approval of relevant institutional review board or ethics committee.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, L., Tian, C., Yang, Y. et al. Practice and principle of traditional Chinese medicine for the prevention and treatment of COVID-19. Front. Med. 17, 1014–1029 (2023). https://doi.org/10.1007/s11684-023-1040-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11684-023-1040-8

Keywords

Search

Navigation